Product Information

Registration Status: Active

INLYTA TABLET 1MG is approved to be sold in Singapore with effective from 2013-11-03. It is marketed by PFIZER PTE LTD, with the registration number of SIN14321P.

This product contains Axitinib 1mg in the form of TABLET, FILM-COATED. It is approved for ORAL use.

This product is manufactured by Pfizer Manufacturing Deutschland GmbH in GERMANY.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.



Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3. Axitinib is marketed under the name Inlyta®, and if one previous systemic therapy for kidney cell cancer has failed, axitinib is indicated.


Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.

Mechanism of Action

Axitinib selectively blocks the tyrosine kinase receptors VEGFR-1 (vascular endothelial growth factor receptor), VEGFR-2, and VEGFR-3.


After one 5 mg dose of axitinib, it takes about 2.5 to 4.1 hours to reach maximum plasma concentration.
The volume of distribution is 160 L.
Axitinib undergoes mainly hepatic metabolism. CYP3A4 and CYP3A5 are the main hepatic enzymes while CYP1A2, CYP2C19, and UGT1A1 enzymes are secondary.


The average clearance of axitinib is 38 L/h.


Some of the more serious toxic effects seen in patients taking axitinib include, but are not limited to, hypertension, thrombotic events, hemorrhage, and GI perforation.

Active Ingredient/Synonyms

axitinib | axitinibum | Axitinib |

Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.


  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank